Inozyme Pharma, Inc.

INZY · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$102-$71-$67-$57
Dep. & Amort.$1$1$1$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$8$7$8$7
Change in WC$5-$3$2$0
Other Non-Cash-$3-$4-$1$0
Operating Cash Flow-$92-$71-$58-$48
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0-$0
Inv. Purchases-$155-$269-$152-$122
Inv. Sales/Matur.$222$216$147$165
Other Inv. Act.$0$0-$0$0
Investing Cash Flow$67-$54-$5$43
Financing Activities
Debt Repay.$0$40$4$0
Stock Issued$11$86$56$1
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1$0$13$1
Financing Cash Flow$11$126$73$1
Forex Effect$0-$0-$0$0
Net Chg. in Cash-$14$2$10-$5
Supplemental Information
Beg. Cash$35$33$24$28
End Cash$21$35$33$24
Free Cash Flow-$92-$71-$58-$49